• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Science, Technology and Human Values >The Neoliberal Regulatory State, Industry Interests, and the Ideological Penetration of Scientific Knowledge: Deconstructing the Redefinition of Carcinogens in Pharmaceuticals
【24h】

The Neoliberal Regulatory State, Industry Interests, and the Ideological Penetration of Scientific Knowledge: Deconstructing the Redefinition of Carcinogens in Pharmaceuticals

机译：新自由主义的监管状态，行业利益和科学知识的意识形态渗透：解构药物中致癌物的重新定义

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It is argued that neoliberal political ideology has redefined the regulatory state to have greater convergence of interests and goals with the pharmaceutical industry than previously, particularly regarding acceleration and cost reduction of drug development and regulatory review. Consequently, the pharmaceutical industry has been permitted to set the agenda about how shorter term and cheaper alternative carcinogenicity testing systems are investigated for validity. The authors contend that, with the tacit approval of the neoliberal regulatory state, the commercial interests of the pharmaceutical industry framed the process and interpretation of validating these new test systems, thereby influencing what counts as knowledge about the carcinogenic status of new pharmaceuticals. While such alternative tests were occasioned by "molecularization," the framing of their validation was not determined by technoscientific logic or a lack of standards of validation, but by the sociopolitical goals of the controlling institutions. Indeed, a different validation process could have been conducted had the priority been to develop carcinogenicity testing in the interests of public-health protection. While the resulting validation indicated that the short-term alternative tests posed small risks to the commercial interests of pharmaceutical firms, they provided little reassurance that patients would not be exposed to greater risks than before from undetected carcinogens.
机译：有人认为，新自由主义的政治意识形态已经重新定义了监管国家，使其与制药行业的利益和目标的融合程度比以前更高，特别是在加速和降低药物开发和监管审查方面。因此，制药行业已被允许就如何研究更短和更便宜的替代致癌性测试系统的有效性制定议程。作者认为，在新自由主义国家的默许下，制药业的商业利益构成了验证这些新测试系统的过程和解释，从而影响了对新药致癌状态的了解。尽管这种替代性测试是通过“分子化”进行的，但其验证的框架并不是由技术科学逻辑或缺乏验证标准来确定的，而是由控制机构的社会政治目标来确定的。的确，如果优先考虑为公共卫生保护发展致癌性测试，则可以采用不同的验证过程。尽管最终的验证表明短期替代测试对制药公司的商业利益构成了很小的风险，但他们无法保证患者不会因未检出的致癌物而面临比以前更大的风险。

著录项

  • 来源
    《Science, Technology and Human Values》 |2012年第5期|p.443-477|共35页
  • 作者

    John Abraham; Rachel Ballinger;

  • 作者单位

    Centre for Research and Health in Medicine (CRHaM), Department of Sociology, University of Sussex, Brighton BN1 9SN, United Kingdom;

    Cancer Research UK, Sussex Psychological Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    politics; power; governance; expertise;

    机译：政治;功率;治理;专长;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号